<DOC>
	<DOCNO>NCT00014235</DOCNO>
	<brief_summary>This clinical trial study fludarabine phosphate total-body radiation follow donor peripheral blood stem cell transplant immunosuppression treat patient hematologic malignancy . Giving chemotherapy total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving total-body irradiation together fludarabine phosphate , cyclosporine , mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Phosphate Total-Body Radiation Followed Donor Peripheral Blood Stem Cell Transplant Immunosuppression Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate rate grade III/IV graft-versus-host disease ( GVHD ) patient treat low-dose total body irradiation ( TBI ) , fludarabine ( fludarabine phosphate ) , PBSC infusion immunosuppression mycophenolate mofetil disease risk-based cyclosporine taper . II . To estimate risk graft rejection , GVHD , disease response , non-relapse mortality incidence severity infectious complication use treatment strategy . OUTLINE : Patients assign 1 2 treatment group . ARM I ( indolent disease ) : CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) day -4 -2 undergo TBI day 0 . TRANSPLANTATION : Patients undergo donor peripheral blood stem cell transplantation ( PBSCT ) day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) twice daily ( BID ) IV every 8-12 hour day -3 56 taper day 180 mycophenolate mofetil PO BID IV every 8-12 hour day 0 27 . ARM II ( aggressive disease ) : CONDITIONING REGIMEN : Patients receive fludarabine phosphate undergo TBI Arm I. TRANSPLANTATION : Patients undergo donor PBSCT day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine PO BID IV every 8-12 hour day -3 56 taper day 70 mycophenolate mofetil Arm I . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Leukemia , Mast-Cell</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Leukemoid Reaction</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients nonHodgkin lymphoma ( NHL ) , chronic lymphocytic leukemia ( CLL ) multiple myeloma eligible curative autologous transplantation receive prior autologous transplantation ; patient NHL CLL must fail prior therapy alkylating agent and/or fludarabine , high risk relapse ; patient multiple myeloma must stage II III disease receive prior chemotherapy Patients &lt; 50 year age NHL , Hodgkin 's disease ( HD ) , CLL multiple myeloma high risk regimen relate toxicity prior autologous transplant preexist medical condition Patients &lt; 75 year age malignant diseases treatable allogeneic bone marrow transplant ( BMT ) preexist chronic disease affect kidney , liver , lung , heart consider high risk regimen relate toxicity use standard high dose regimen ; follow disease likely candidate Myelodysplastic syndrome Myeloproliferative syndrome Acute Leukemia &lt; 10 % blast Amyloidosis Hodgkin 's disease The Fred Hutchinson Cancer Research Center ( FHCRC ) Patient Care Conference ( PCC ) may approve patient malignancy patient decline standard allograft transplant follow presentation approval ; center outside FHCRC PCC equivalent obtain Institutional approval ; comparable group Institution , please contact FHCRC Principal Investigator FHCRC approval PCC DONOR : Human leukocyte antigen ( HLA ) genotypically phenotypically identical relate donor DONOR : Donor must consent filgrastim ( GCSF ) administration leukapheresis DONOR : Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) Eligible highpriority curative autologous transplant Patients rapidly progressive aggressive NHL unless minimal disease state Any current central nervous system ( CNS ) involvement disease Fertile men woman unwilling use contraceptive technique 12 month follow treatment Females pregnant Patients human immunodeficiency virus ( HIV ) positive Cardiac ejection fraction &lt; 40 % ; ejection fraction require patient history anthracyclines history cardiac disease Receiving supplementary continuous oxygen Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 30 % Total lung capacity ( TLC ) &lt; 30 % Forced expiratory volume one second ( FEV1 ) &lt; 30 % Total bilirubin &gt; 2x upper limit normal Serum glutamate pyruvate transaminase ( SGPT ) serum glutamic oxaloacetic transaminase ( SGOT ) 4x upper limit normal Karnofsky score &lt; 50 Patients poorly control hypertension unable blood pressure keep 150/90 standard medication Patients renal failure eligible , however patient renal compromise ( serum creatinine great 2.0 ) likely compromise renal function may require hemodialysis ( may permanent ) due need maintain adequate serum cyclosporine level The addition cytotoxic agent `` cytoreduction '' exception hydroxyurea imatinib mesylate allow within two week initiation condition DONOR : Identical twin DONOR : Age le 12 year DONOR : Pregnancy DONOR : Infection HIV DONOR : Inability achieve adequate venous access DONOR : Known allergy GCSF DONOR : Current serious systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>